Drug intelligence / Profile preview

TBL-100

Development stage: Preclinical
Lead developer: Tau Bio-Logic
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

TBL-100 is a high-affinity humanized monoclonal antibody developed by TAU BIO-LOGIC. It targets the tauC3 protein and is being advanced as a potential disease-modifying therapy for neurodegenerative conditions, specifically Alzheimer's disease and Progressive Supranuclear Palsy. LifeArc collaborated with TAU BIO-LOGIC to humanize the antibody, resulting in a lead candidate with high affinity and specificity for tauC3.

Targets

TauC3 (Tau truncated at Asp421)

Beyond the preview

Go deeper on TBL-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBL-100.

Explore the full profile